Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on July 29, 2014. The filing serves as a report of a foreign private issuer pursuant to Rule 13A-16 under the Securities Exchange Act of 1934. The primary purpose of this specific filing is to disclose a corporate governance update regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes
The material change disclosed in this filing is the addition of financial expertise to the company's Board of Directors. No financial performance changes or operational shifts are detailed in this specific text.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. The content is limited to the announcement of the board composition change.
Key Facts for Investor Verification
- The company added a new member with financial expertise to its Board of Directors.
- The filing was signed by Dennis Bourgeault, Chief Financial Officer, on July 29, 2014.
- No financial data or operational metrics are included in this specific Form 6-K.